Multi-modality surveillance. Comprehensive monitoring for kidney transplant patients, combining dd-cfDNA, and gene expression profiling, and machine learning driven prognostic assessment.
Cell-free DNA is fragmented DNA originating from cells and continuously released into the bloodstream
AlloSure Kidney measures cfDNA, and uses single nucleotide polymorphisms (SNPs) to distinguish between donor and recipient.
AlloSure can quantify increasing levels of dd-cfDNA, serving as a leading indicator of graft injury
Establishing a baseline AlloSure reading allows comparison against subsequent tests. The study conducted by Bromberg, et al. established a 61% reference value (RCV) for AlloSure8
The DART study established the AlloSure Routine Testing Schedule (ARTS). The schedule ensures testing at key clinical time points post-transplant and then quarterly surveillance testing9.
Multi-modality surveillance. Comprehensive monitoring for kidney transplant patients, combining dd-cfDNA, and gene expression profiling, and machine learning driven prognostic assessment.